“Brain-Specific” Nutrients: A Memory Cure?

Psychological Science in the Public Interest

Volumn 3, Issue 1, 2002, Pages 12-38

  Mcdaniel, Mark A ^a   Maier, Steven F ^b   Einstein, Gilles O ^c  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c FURMAN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84996154346     PISSN: 15291006     EISSN: 15396053     Source Type: Journal    
DOI: 10.1111/1529-1006.00007     Document Type: Article

References (116)

1. Abuzzahab F.S., Sr.Merwin G.E., Zimmerman R.L., Sherman M.C. (1977). A double blind investigation of piracetam (Nootropil) vs placebo in geriatric memory. Pharmakopsychiatry, 10, 49–56.
2. Agnoli A., Bruno G., Fioravanti M. (1989). Therapeutic approach to senile memory impairment: A double-blind clinical trial with CDP-choline. In Ed. Wurtman R.J., Corkin S., Growdon J.H., Ritter-Walker E. (Eds.), Alzheimer's Disease: Proceedings of the fifth meeting of the International Study Group on the Pharmacology of Memory Disorders Associated With Aging (pp. 649–654). Boston: Birkhauser.
3. Aureli T., Miccheli A., Ricciolini R. (1990). Aging brain: Effect of acetyl-carnitine treatment on rat brain energy and phospholipid metabolism: A study by NMR spectroscopy. Brain Research, 526, 108–112.
4. Balestreri R., Fontuna L., Astengo F. (1987). A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. Journal of the American Geriatric Society, 35, 130–425.
5. Barnes C.A., Markowska A.L., Ingram D.K., Kametani H., Spengler E.L., Lemken V.J., Olton D.S. (1990). Acetyl-L-carnitine 2: Effects on learning and memory performance of aged rats in simple and complex mazes. Neurobiology of Aging, 11, 499–506.
6. Bartus R.T., Dean R.L., Sherman K.A., Friedman E., Beer B. (1981). Profound effects of combining choline and piracetam on memory enhancement and cholinergic function in aged rats. Neurobiology of Aging, 2, 105–111.
7. Becker R.E., Giacobini E. (1988). Mechanisms of cholinesterase inhibition in senile dementia of the Alzheimer type: Clinical, pharmacological, and therapeutic aspects. Drug Development Research, 12, 163–195.
8. Benton D., Fordy J., Haller J. (1995). The impact of long-term vitamin supplementation on cognitive functioning. Psychopharmacology, 117, 298–305.
9. Blessed G., Tomlinson B.E., Roth M. (1968). The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. British Journal of Psychiatry, 114, 797–811.
10. Blusztajn J.K., Richardson U.I., Liscovitch M., Mauron C., Wurtman R.J. (1987). Phospholipids in cellular survival and growth. In Ed. Hanin I., Ansell G.B. (Eds.), Lecithin: Technological, biological, and therapeutic aspects (pp. 85–94). New York: Plenum Press.
11. Brooks J.O., Yesavage J.A., Carta A., Bravi D. (1998). Acetyl-L-carnitine slows decline in younger patients with Alzheimer's disease: A reanalysis of a double-blind, placebo-controlled study using the trilinear approach. International Psychogeriatrics, 10, 193–203.
12. Buschke H., Fuld P.A. (1974). Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology, 24, 1019–1025.
13. Carta A., Calvani M. (1991). Acetyl-L-carnitine: A drug able to slow the progress of Alzheimer's disease? Annals of the New York Academy of Sciences, 640, 228–232.
14. Casamenti F., Scali C., Pepeu G. (1991). Phosphatidylserine reverses the age-dependent decrease in cortical acetylcholine release: A microdialysis study. European Journal of Pharmacology, 194, 11–16.
15. Castornia M., Ambrosini A.M., Pacific L., Ramacci M.T., Angelucci L. (1994). Age-dependent loss of NMDA receptors in hippocampus, striatum, and frontal cortex of the rat: Prevention by acetyl-L-carnitine. Neurochemical Research, 19, 795–798.
16. Cenacchi T., Bertoldin T., Farina C., Fiori M.G., Crepaldi G. (1993). Cognitive decline in the elderly: A doubleblind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration. Aging Clinical Experimental Research, 5, 123–133.
17. Chaudhry H.R., Najam N.de Mahieu C., Raza A., Ahmad N. (1992). Clinical use of piracetam in epileptic patients. Current Therapeutic Research, 52, 355–360.
18. Cohen S.A.Müller W.E. (1992). Age-related alterations of NMDA-receptor properties in the mouse forebrain: Partial restoration by chronic phos-phatidylserine treatment. Brain Research, 584, 174–180.
19. Cohen S.A.Müller W.E. (1993). Effects of piracetam on NMDA receptor properties in the aged mouse brain. Pharmacology, 47, 217–222.
20. Craik F.I.M. (1986). A functional account of age differences in memory. In Ed. Klix F., Hangendorf H. (Eds.), Human memory and cognitive capabilities: Mechanisms and performances (pp. 409–422). Amsterdam: Elsevier.
21. Croisile B., Trillet M., Fonderai J., Laurent B., Mauguiere F., Billardon M. (1993). Long-term and high-dose piracetam treatment of Alzheimer's disease. Neurology, 43, 301–305.
22. Crook T.H. III Adderly B. (1998). The memory cure. New York: Simon & Schuster.
23. Crook T.H., Petrie W., Wells C., Massari D.C. (1992). Effects of phosphatidylserine in Alzheimer's Disease. Psychopharmacology Bulletin, 28, 61–65.
24. Crook T.H., Tinklenberg J., Yesavage J., Petrie W., Nunzi M.G., Massari D.C. (1991). Effects of phosphatidylserine in age-associated memory impairment. Neurology, 41, 644–649.
25. DeNoble V.J. (1987). Vinpocetine enhances retrieval of a step-through passive avoidance response in rats. Pharmacology, Biochemistry, and Behavior, 26, 183–186.
26. Dinsdale J.R.M., Griffiths G.K., Castello J., Ortiz J.A., Maddock J., Aylward M. (1983). C-CDP-choline repeated oral dose tolerance studies in adult healthy volunteers. Drug Research, 33, 1066–1070.
27. Einstein G.O., McDaniel M.A. (in press). Empowering memory as you age: The real story. New Haven, CT: Yale University Press.
28. Engel R.R., Satzger W., Günther W., Kathmann N., Bove D., Gerke S., Münch U., Hippius H. (1992). Double-blind cross-over study of phosphatidylserine vs. placebo in patients with early dementia of the Alzheimer type. European Neuropsychopharmacology, 2149–2155.
29. Erzigkeit H. (1986). Manual zum SKT, Formen A-E. Ebersburg, Germany: VLESS-Verlagsgesellshaft.
30. Finch C.E., Cohen D.M. (1997). Aging, metabolism, and Alzheimer's disease: Review and hypotheses. Experimental Neurology, 14102–14382.
31. Fonlupt P., Martinet M., Pacheco H. (1985). Effect of CDP-choline on dopamine metabolism in central nervous system. In Ed. Zappia V., Kennedy E.P., Nilsson B.I., Galetti P. (Eds.), Novel biochemical, pharmacological, and clinical aspects of CDP-choline (pp. 169–177). New York: Elsevier.
32. Foy M.R., Henderson V.W., Berger T.W., Thompson R.F. (2000). Estrogen and neural plasticity. Current Directions in Psychological Science, 9, 148–152.
33. Gabryel B., Trzeciak H.I. (1994). Nootropics: Pharmacological properties and therapeutic use. Polish Journal of Pharmacology, 46, 383–394.
34. Ghirardi O., Milano S., Ramacci M.T., Angelucci L. (1989). Long-term acetyl-L-carnitine preserves spatial learning in the senescent rat. Progress in Neuropsychopharmacology and Biological Psychiatry, 13, 237–245.
35. Giurgea C., Mouravieff-Lesuisse F. (1972). Effet facilitateur du piracetam sur un apprentissage repetitif chez le rat. Journal of Pharmacology, 3, 17–30.
36. Goldman R., Klatz R., Berger L. (1999). Brain fitness. New York: Doubleday.
37. Goodwin J.S., Goodwin J.M., Garry P.J. (1983). Association between nutritional status and cognitive functioning in a healthy elderly population. Journal of the American Medical Association, 249, 2917–2921.
38. Greenwald A.G., Spangenberg E.R., Pratkanis A.R., Eskenazi J. (1991). Double-blind tests of subliminal self-help audiotapes. Psychological Science, 2, 119–122.
39. Growdon J.H. (1987). Use of phosphatidylcholine in brain diseases: An overview. In Ed. Hanin I., Ansell G.B. (Eds.), Lecithin: Technological, biological, and therapeutic aspects (pp. 121–136). New York: Plenum Press.
40. Growdon J.H., Corkin S., Huff F.J., Rosen T.J. (1986). Piracetam combined with lecithin in the treatment of Alzheimer's disease. Neurobiology of Aging, 7, 269–276.
41. Henderson V.W. (2000). Hormone therapy and the brain: A clinical perspective on the role of estrogen. New York: Parthenon Publishing.
42. Hindmarch I., Fuchs H.-H., Erzigkeit H. (1991). Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. International Clinical Psychopharmacology, 6, 31–43.
43. Hirshman E., Wells E., Wierman M.E., Anderson B., Butler A., Senholzi M., Fisher J.(in press). The effect of dehydroepiandrosterone (DHEA) on recognition memory decision processes and discrimination in post-menopausal women. Psychonomic Bulletin & Review.
44. Imperato A., Ramacci M.T., Angelucci L. (1989). Acetyl-L-carnitine enhances acetylcholine release in the striatum and hippocampus of awake freely moving rats. Neuroscience Letters, 107, 251–255.
45. Intons-Peterson M.J., Rocchi P., West T., McLellan K., Hackney A. (1999). Age, testing at preferred or nonpreferred times (testing optimality), and false memory. Journal of Experimental Psychology: Learning, Memory, and Cognition, 25, 23–40.
46. Israel L., Melac M., Milinkevitch D., Dubos G. (1994). Drug therapy and memory training programs: A double-blind randomized trial of general practice patients with age-associated memory impairment. International Psychogeriatrics, 6, 155–170.
47. Jacobs J.D., Bernhard M.R., Delgado A., Strain J.J. (1977). Screening for organic mental syndromes in the medically ill. Annals of Internal Medicine, 86, 40–46.
48. Joseph J.A., Shukitt-Hale B., Denisova N.A., Bielinski D., Martin A., McEwen J.J., Bickford P.C. (1999). Reversals of age-related declines in neuronal signal transduction, cognitive, and motor behavioral deficits with blueberry, spinach, or strawberry diet supplementation. Journal of Neuroscience, 19, 8114–8121.
49. Joseph J.A., Shukitt-Hale B., Denisova N.A., Prior R.L., Cao G., Martin A., Taglialatela G., Bickford P.C. (1998). Long-term dietary strawberry, spinach, or vitamin E supplementation retards the onset of age-related neuronal signal transduction and cognitive behavioral deficits. Journal of Neuroscience, 18, 8047–8055.
50. Joseph J.A., Villalobos-Molina R., Denisova N., Erat S., Cutler R., Strain J.G. (1996). Age differences in sensitivity to H2O2- or NO-induced reductions in K+evoked dopamine release from superfused striatal slices: Reversal by PBN or trolox. Free Radical Biology in Medicine, 20, 821–830.
51. Kalmijn S., Launer L.J., Stolk R.P., De Jong F.H., Pols H.A.P., Hofman A., Breteler M.M.B., Lamberts S.W.J. (1998). A prospective study on cortisol, dehydroepiandrosterone sulfate, and cognitive function in the elderly. Journal of Clinical Endocrinology and Metabolism, 83, 3487–3492.
52. Kemper T.L. (1994). Neuroanatomical and neuropathological changes during aging and dementia. In Ed. Albert M.L., Knoepfer E.J.E. (Eds.), Clinical neurology of aging (2nd ed., pp. 3–67). New York: Oxford University Press.
53. Khalsa D.S. (1998). Integrated medicine and prevention and reversal of memory loss. Alternative Therapies in Health and Medicine, 4, 38–43.
54. Kidd P.M. (1999). A review of nutrients and botanicals in the integrative management of cognitive dysfunction. Alternative Medicine Review, 4, 144–161.
55. Kieburtz K., McDermott M., Como P., Growdon J., Brady J., Carter J., Huber S., Kanigan B., Landow E., Rudolph A., Saint-Cyr J., Stern Y., Tennis M., Thelen J., Shoulson I.the Parkinson Study Group. (1994). The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Neurology, 44, 1756–1759.
56. Kramer A.F., Hahn S., Cohen N.J., Banich M.T., McAuley E., Harrison C.R., Chason J., Vakil E., Bardell L., Boileau R.A., Colcombe A. (1999). Aging, fitness and neurocognitive function. Nature, 400, 418–419.
57. La Rue A., Koehler K.M., Wayne S.J., Chiulli S.J., Haaland K.Y., Garry P.J. (1997). Nutritional status and cognitive functioning in a normally aging sample: A 6-y reassessment. American Journal of Clinical Nutrition, 65, 20–29.
58. Ladd S.L., Sommer S.S. (1990, August). Phosphatidylcholine enhances short-term memory in slow learners. Paper presented at the annual meeting of the American Psychological Association, Boston.
59. LeBlanc E.S., Janowsky J., Chan B.K.S., Nelson H.D. (2001). Hormone replacement therapy and cognition: Systematic review and meta-analysis. Journal of the American Medical Association, 285, 1489–1499.
60. Lee S.H., Oe T., Blair I.A. (2001). Vitamin C-induced decomposition of lipid hydroperoxides to endogenous genotoxins. Science, 292, 2083–2086.
61. Livingston G.A., Sax K.B., McClenahan Z., Blumenthal E., Foley K., Willison J., Mann A.H., James I.M. (1991). Acetyl-l-carnitine in dementia. International Journal of Geriatric Psychiatry, 6, 853–860.
62. Lopez G.-C.I., Agut J., Ortiz A., Wurtman R.J. (1992). Effects of orally-administered cytidine 5'-diphosphate choline on brain phospholipid content. Journal of Nutritional Biochemistry, 3, 313–315.
63. Manconi E., Binaghi F., Pitzus F. (1986). A double-blind clinical trial of vinpocetine in the treatment of cerebral insufficiency of vascular and degenerative origin. Current Therapeutic Research, 40, 702–709.
64. Markowska A.L., Ingram D.K., Barnes C.A., Spangler E.L., Lemken V.J., Kametani H., Yee W., Olton D.S. (1990). Acetyl-L-carnitine 1: Effects on mortality, pathology and sensory-motor performance in aging rats. Neurobiology of Aging, 11, 491–498.
65. Masotto C., Apud J.A., Racagni G. (1985). Neurochemical studies on GABAergic and aminergic systems in the rat brain following acute and chronic piracetam administration. Pharmacology Research Communications, 17, 749–772.
66. May C.P., Hasher L., Stoltzfus E.R. (1993). Optimal time of day and the magnitude of age differences in memory. Psychological Science, 4, 326–330.
67. McAllister A.K., Katz L.C., Lo D.C. (1999). Neurotrophins and synaptic plasticity. Annual Review of Neuroscience, 22, 295–318.
68. McDaniel M.A., Einstein G.O., Lollis T. (1988). Qualitative and quantitative considerations in encoding difficulty effects. Memory & Cognition, 16, 8–14.
69. Mohs R.C., Rosen W.G., Davis K.L. (1983). The Alzheimer's Disease Assessment Scale: An instrument for assessing treatment efficacy. Psychopharmacology Bulletin, 19, 448–450.
70. Nicholson C.D. (1990). Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia. Psychopharmacology, 101, 147–159.
71. Nunzi M.G., Milan F., Guidolin D., Toffano G. (1987). Dendritic spine loss in hippocampus of aged rats: Effects of brain phosphatidylserine administration. Neurobiology of Aging, 8, 501–510.
72. Nybaeck H., Wiesel F.-A., Skett P. (1979). Effects of piracetam on brain monoamine metabolism and serum prolactin levels in the rat. Psychopharmacology, 61, 235–238.
73. Palmieri G., Palmieri R., Inzoli M.R., Lombardi G., Sottini C., Tavolato B., Giometto B. (1987). Double-blind controlled trial of phosphatidylserine in patients with senile mental deterioration. Clinical Trials Journal, 24, 73–83.
74. Pascale A., Govoni S., Battaini F. (1998). Age-related alterations of PKC, a key enzyme in memory processes: Physiological and pathological examples. Molecular Neurobiology, 16, 49–62.
75. Pascale A., Milano S., Corsico N., Lucchi L., Battaini F., Martelli E.A., Trabucchi M., Govoni S. (1994). Protein kinase C activation and anti-amnestic effect of acetyl-L-carnitine: In vitro and in vivo studies. European Journal of Pharmacology, 265, 1–7.
76. Pepeu G., Spignoli G. (1989). Neurochemical actions of “nootropic drugs.” In Ed. Wurtman R.J., Corkin S., Growdon J.H., Ritter-Walker E. (Eds.), Alzheimer's Disease: Proceedings of the fifth meeting of the International Study Group on the Pharmacology of Memory Disorders Associated With Aging (pp. 387–398). Boston: Birkhauser.
77. Perkins A.J., Hendrie H.C., Callahan C.M., Gao S., Unverzagt F.W., Xu Y., Hall K.S., Hui S.L. (1999). Association of antioxidants with memory in a multiethnic elderly sample using the Third National Health and Nutrition Examination Survey. American Journal of Epidemiology, 150, 37–44.
78. Perrig W.J., Perrig P., Stahelin H.B. (1997). The relation between antioxidants and memory performance in the old and very old. Journal of the American Geriatric Society, 45, 718–724.
79. Platel A., Jalfre M., Pawelec C., Roux S., Porsett R.D. (1984). Habituation of exploratory activity in mice: Effects of combinations of piracetam and choline on memory processes. Pharmacology, Biochemistry, and Behavior, 21, 209–212.
80. Postman L. (1962). The temporal course of proactive inhibition for serial lists. Journal of Experimental Psychology, 63, 361–369.
81. Postman L., Hasher L. (1972). Conditions of proactive inhibition in free recall. Journal of Experimental Psychology, 92, 276–284.
82. Quinn J., Kaye J. (1998). Treatment of Alzheimer's Disease. Mediguide to Geriatric Neurology, 2, 1–8.
83. Rai G., Wright G., Scott L., Beston B., Rest J., Exton-Smith A.N. (1990). Double-blind, placebo controlled study of acetyl-l-carnitine in patients with Alzheimer's dementia. Current Medical Research and Opinion, 11, 638–647.
84. Raz N. (2000). Aging of the brain and its impact on cognitive performance: Integration of structural and functional findings. In Ed. Craik F.I.M., Salthouse T.A. (Eds.), Handbook of aging and cognition (pp. 1–90). Mahwah, NJ: Erlbaum.
85. Rey A. (1970). L'examen clinique en psychologie. Paris: Presses Universitaires de Paris.
86. Rischke R., Krieglstein J. (1991). Protective effect of vinpocetine against brain damage caused by ischemia. Japanese Journal of Pharmacology, 56, 349–356.
87. Salthouse T.A. (1982). Adult cognition: An experimental psychology of human aging. New York: Springer-Verlag.
88. Sano M., Ernesto C., Thomas R.G., Klauber M.R., Schafer K., Grundman M., Woodbury P., Growdon J., Cotman C.W., Pfeiffer E., Schneider L.S., Thal L.J. (1997). A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. New England Journal of Medicine, 336, 1216–1222.
89. Sara S.J., David-Remacie M. (1974). Recovery from electroconvulsive shock-induced amnesia by exposure to the training environment: Pharmacological enhancement by piracetam. Psychopharmacologia, 36, 59–66.
90. Sara S.J., Lefevre D. (1972). Hypoxia-induced amnesia in one-trial learning and pharmacological protection by piracetam. Psychopharmacologia, 25, 32–40.
91. Savci V., Wurtman R.J.W. (1995). Effect of cytidine on membrane phospholipid synthesis in rat striatal slices. Brain Research, 64, 378–384.
92. Schiffer R. (1999). Can memory loss be stopped? Journal of Longevity, 5, 24–26.
93. Schindler U., Rush D.K., Fielding S. (1984). Nootropic drugs: Animal models for studying effects on cognition. Drug Development Research, 4, 567–576.
94. Shimamura A.P., Jurica P.J., Mangels J.A., Gershberg F.B. (1995). Susceptibility to memory interference effects following frontal lobe damage: Findings from tests of paired-associate learning. Journal of Cognitive Neuroscience, 7, 144–152.
95. Smith A.D., Earles J.L. (1996). Memory changes in normal aging. In Ed. Hess T., Blanchard-Fields F. (Eds.), Cognitive changes in adulthood and aging (pp. 192–220). New York: McGraw-Hill.
96. Smith R.C., Vroulis G., Johnson R., Morgan R. (1984). Comparison of therapeutic response to long-term treatment with lecithin versus piracetam plus lecithin in patients with Alzheimer's disease. Psychopharmacology Bulletin, 20, 542–545.
97. Spagnoli A., Lucca U., Menasce G., Bandera L., Cizza G., Forloni G., Tettamanti M., Frattura L., Tiraboschi P., Comelli M., Senin U., Longo A., Petrini A., Brambilla G., Belloni A., Negri C., Cavazzuti F., Slasi A., Calogero P., Parma E., Stramba-Badiale M., Vitali S., Andreoni G., Inzoli M.R., Santus G., Caregnato R., Peruzza M., Favaretto M., Bozeglav C., Alberoni M., De Leo D., Serraiotto L., Baiocchi A., Scoccia S., Culotta P., Ieracitano D. (1991). Long-term acetyl-L-carnitine treatment in Alzheimer's disease. Neurology, 41, 1726–1732.
98. Spiers P.A., Myers D., Hochanadel G.S., Lieberman H.R., Wurtman R.J. (1996). Citicoline improves verbal memory in aging. Archives of Neurology, 53, 441–448.
99. Subhan Z., Hindmarch I. (1985). Psychopharmacological effects of vinpocetine in normal healthy volunteers. European Journal of Clinical Pharmacology, 28, 567–571.
100. Swets J.A., Dawes R.M., Monahan J. (2000). Psychological science can improve diagnostic decisions. Psychological Science in the Public Interest, 1 (1).
101. Szakall S., Boros I., Balkay L., Emri M., Fekete I., Kerenyi L., Lehel S., Marian T., Molnar T., Varga J., Galuska L., Tron L., Bereczki D., Csiba L., Gulyas B. (1998). Cerebral effects of a single dose of intravenous vinpocetine in chronic stroke patients: A PET study. Journal of Neuroimaging, 8, 197–204.
102. Tempesta E., Troncon R., Janiri L., Colusso L., Riscica P., Saraceni G., Gesmundo E., Calvani M., Benedetti N., Pola P. (1990). Role of acetyl-L-carnitine in the treatment of cognitive deficit in chronic alcoholism. International Journal of Clinical Pharmacology Research, 10, 101–107.
103. Thal L.J., Calvani M., Amato A., Carta A. (2000). A 1-year controlled trial of acetyl-L-carnitine in early onset Alzheimer's Disease. Neurology, 55, 805–810.
104. Thal L.J., Carta A., Clarke W.R., Ferris S.H., Friedland R.P., Petersen R.C., Pettegrew J.W., Pfeiffer E., Raskind M.A., Sano M., Tuszynski M.H., Woolson R.F. (1996). A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's Disease. Neurology, 47, 705–711.
105. Thal L.J., Salmon D.P., Lasker B., Bower D., Klauber M.R. (1989). The safety and lack of efficacy of vinpocetine in Alzheimer's disease. Journal of the American Geriatrics Society, 37, 515–520.
106. Toffano G. (1987). The therapeutic value of phosphatidylserine effect in the aging brain. In Ed. Hanin I., Ansell G.B. (Eds.), Lecithin: Technological, biological, and therapeutic aspects (pp. 137–146). New York: Plenum Press.
107. Tyler S., Hertel P., McCallum M., Ellis H. (1979). Cognitive effort and memory. Journal of Experimental Psychology: Human Learning and Memory, 5, 607–617.
108. Valzelli L., Bernasconi S., Coen E., Penkov E. (1980). Effect of different psychoactive drugs on serum and brain tryptophan levels. Neuropsychobiology, 6, 224–229.
109. Villardita C., Grioli S., Salmeri G., Nicoletti F., Pennisi G. (1987). Multi-centre clinical trial of brain phosphatidylserine in elderly patients with intellectual deterioration. Clinical Trials Journal, 24, 84–93.
110. Wecker L. (1989). Dietary choline: A limiting factor for the synthesis of ACh by the brain. In Ed. Wurtman R.J., Corkin S., Growdon J.H., Ritter Walker E. (Eds.), Alzheimer's Disease: Proceedings of the fifth meeting of the International Study Group on the Pharmacology of Memory Disorders Associated With Aging (pp. 221–231). Boston: Birkhauser.
111. Wesnes K.A., Ward T., McGinty A., Petrini O. (2000). The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers. Psychopharmacology, 152, 353–361.
112. West R.L. (1996). An application of prefrontal cortex function theory of cognitive aging. Psychological Bulletin, 120, 272–292.
113. Wolf O.T., Neumann O., Hellhammer H.D., Geiben A.C., Strasburger C.J., Dressendorfer R.A., Pirke K.M., Kirschbaum C. (1997). Effects of a two-week physiological dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly women and men. Journal of Clinical Endocrinology and Metabolism, 82, 2363–2367.
114. Wurtman J.J. (1979). Sources of choline and lecithin in the diet. In Ed. Barbeau A., Growdon J.H., Wurtman R.J. (Eds.), Nutrition and the brain, Vol. 5 (pp. 73–81). New York: Raven Press.
115. Wurtman R.J., Hefti F., Melamed E. (1981). Precursor control of neurotransmitter synthesis. Pharmacology Review, 32, 315–335.
116. Zanotti A., Valzelli L., Toffano G. (1989). Chronic phosphatidylserine treatment improves spatial memory and passive avoidance in aged rats. Psychopharmacology, 99, 316–321.